Trust Co. of Vermont Invests $1.25 Million in Novo Nordisk A/S $NVO

Trust Co. of Vermont bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 26,069 shares of the company’s stock, valued at approximately $1,250,000.

A number of other hedge funds and other institutional investors have also modified their holdings of NVO. Godfrey Financial Associates Inc. purchased a new position in Novo Nordisk A/S in the 4th quarter worth about $25,000. WealthCollab LLC lifted its stake in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares in the last quarter. Transamerica Financial Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 201.5% in the fourth quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock worth $31,000 after buying an additional 403 shares during the period. Quaker Wealth Management LLC boosted its holdings in shares of Novo Nordisk A/S by 186.0% in the fourth quarter. Quaker Wealth Management LLC now owns 615 shares of the company’s stock worth $31,000 after buying an additional 400 shares during the period. Finally, Oakworth Capital Inc. increased its position in shares of Novo Nordisk A/S by 41.6% in the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after acquiring an additional 182 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.9%

NYSE:NVO opened at $45.71 on Wednesday. The stock has a market cap of $204.10 billion, a PE ratio of 11.18, a price-to-earnings-growth ratio of 4.15 and a beta of 0.76. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The stock’s 50-day moving average is $47.51 and its two-hundred day moving average is $44.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The business had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be given a $0.5786 dividend. The ex-dividend date is Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio is presently 42.79%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets restated a “market perform” rating and set a $47.00 price target on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Berenberg Bank set a $47.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, August 12th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Finally, Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Four analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $64.94.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.